Anti-CD38 isatuximab immunotherapy in hidradenitis suppurativa: a randomized, double-blinded, placebo-controlled, seamless phase 2A/2B trial

Active Cooperative Agreement Awarded

Award ID
UH3AR085895
Recipient
Awarding agency
Obligated
$2,071,075

Award facts

Completion date 4% complete
Place of performance
East Lansing, MI 48824, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Michigan State University, doing business as Henry Ford Health+Michigan State University Health Sciences, $2.071075 million under Cooperative Agreement UH3AR085895 on September 9, 2026. The award is funded under Assistance Listing 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, whose NIAMS mission supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases.

The award funds an investigator-initiated, randomized, double-blinded, placebo-controlled, seamless Phase 2A/2B trial of the anti-CD38 immunotherapy isatuximab in patients with severe hidradenitis suppurativa (Hurley stage III) who failed adalimumab and have high CD38 expression in blood or skin. Aim 1 (Phase UG3) delivers the trial start-up milestones, including finalizing regulatory compliance and protocols and securing operational readiness. Aim 2 (Phase UH3) establishes efficacy and safety, with short-term efficacy as the primary endpoint.

The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2031. Place of performance is East Lansing, Michigan 48824.

Description

Abstract
Hidradenitis suppurativa (HS) is a significant health concern affecting a notable portion of the U.S. Population, with higher prevalence and severity in females and african americans. Despite its significant impact on morbidity, current treatments often yield inconsistent results. CD38, a protein involved in immune regulation, was elevated on multiple cell types in various autoimmune and autoinflammatory conditions. Notably, anti-CD38 immunotherapy, available as daratumumab and isatuximab, has been FDA-approved for refractory multiple myeloma and used off-label for various autoimmune and autoinflammatory conditions, including lupus. Our preliminary findings indicate increased CD38 expression in HS patients, particularly in specific immune cells and skin lesions. EX-vivo experiments with an anti-CD38 antibody showed promising reductions in inflammatory markers, emerging as a potential target for HS treatment. To test the therapeutic efficacy and safety of anti- CD38 immunotherapy isatuximab in patients with HS, we propose an investigator-initiated, randomized, double- blinded, placebo-controlled, seamless phase 2A/2B trial in patients with severe HS (hurley stage III disease) who failed adalimumab and have high CD38 expression in the blood or skin. We hypothesize that anti-CD38 immunotherapy could be an effective and safe treatment for patients with HS. We will evaluate our hypothesis through the following aims: aim 1 (phase UG3): accomplish the required milestones for the anti-CD38 immunotherapy clinical trial start-up phase, including finalizing regulatory compliance and protocols as well as securing operational readiness. Aim 2 (phase UH3): establish both the efficacy and safety of anti-CD38 immunotherapy in patients with HS by evaluating short-term efficacy as the primary endpoint [HS clinical response (HISCR) 50 at week 20] and long-term efficacy through multiple secondary endpoints by comparing valid outcome measures at week 36. Safety and tolerability will be assessed as secondary endpoints by comparing adverse events in the treatment and placebo arms. Aim 3 (phase UH3): identify biomarkers to predict the response to anti-CD38 immunotherapy in HS using advanced profiling techniques. The results of this trial will inform the feasibility and effectiveness of anti-CD38 immunotherapy in HS management, guiding the design of future larger-scale clinical trials.

Quick answers

Who received award UH3AR085895?

UH3AR085895 was awarded to Michigan State University by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 9, 2026.

How much is award UH3AR085895 worth?

$2,071,075 has been obligated on UH3AR085895.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award